{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T04:49:45Z","timestamp":1767934185924,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Timely identification of drug-induced Parkinson-like events is essential to improve clinical management and enhance patients\u2019 quality of life. However, there is a significant lack of studies addressing these events in real-world settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To bridge this gap, we analyzed adverse event (AE) reports related to Parkinson-like events from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the first quarter of 2024. Our objective was to summarize a list of potential drugs at high risk for Parkinson-like events and their corresponding proportions of AE reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As a result, a total of 54,639 AE reports linked to Parkinson-like events involving 1,224 drugs were identified. Among these, carbidopa\/levodopa exhibited the highest number of reports, followed by baclofen and pimavanserin. The most frequently reported drug class was antiparkinsonian drugs and psycholeptics, followed by psychoanaleptics. Using two disproportionate analysis methods, the reporting odds ratio and proportional reporting ratio, we found that 136 drugs exhibited positive results in both methods, while 1,063 drugs did not show any positive signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides a comprehensive pharmacovigilance analysis of drugs associated with Parkinson-like events, aiming to promote rational drug use and inform clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1529260","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:47:30Z","timestamp":1735886850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS"],"prefix":"10.3389","volume":"15","author":[{"given":"Ke","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingquan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlu","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa\u2010induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/awz344","article-title":"Evolving concepts on bradykinesia","volume":"143","author":"Bologna","year":"2020","journal-title":"Brain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3389\/fphar.2019.00975","article-title":"Ontological and non-ontological resources for associating medical dictionary for regulatory activities terms to SNOMED clinical terms with semantic properties","volume":"10","author":"Bousquet","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti\u2010HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int. J. Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2019.12.011","article-title":"Drug-induced parkinsonism: revisiting the epidemiology using the WHO pharmacovigilance database","volume":"70","author":"de Germay","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40263-015-0306-3","article-title":"Carbidopa\/levodopa er capsules (Rytary(\u00ae), Numient\u2122): a review in Parkinson's disease","volume":"30","author":"Greig","year":"2016","journal-title":"CNS Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/jcp.0000000000000911","article-title":"Association of antidepressant use with drug-related extrapyramidal symptoms: a pharmacoepidemiological study","volume":"38","author":"Guo","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/molecules23010040","article-title":"Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019s disease","volume":"23","author":"Haddad","year":"2017","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson's disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-019-01201-1","article-title":"Levodopa\/carbidopa enteral suspension: a review in advanced Parkinson\u2019s disease","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System","volume":"84","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1007\/s12035-022-02780-z","article-title":"Neuroanatomical, biochemical, and functional modifications in brain induced by treatment with antidepressants","volume":"59","author":"Khushboo","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0000000000002509","article-title":"Levodopa therapy for Parkinson disease: a look backward and forward","volume":"86","author":"LeWitt","year":"2016","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA Adverse Event Reporting System database","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"20420986221125006","DOI":"10.1177\/20420986221125006","article-title":"Pharmacovigilance: reporting requirements throughout a product\u2019s lifecycle","volume":"13","author":"Lucas","year":"2022","journal-title":"Ther. Adv. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1756285617737728","DOI":"10.1177\/1756285617737728","article-title":"Extended-release oral capsule of carbidopa\u2013levodopa in Parkinson disease","volume":"11","author":"Margolesky","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s11357-022-00707-z","article-title":"The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases","volume":"45","author":"Mensah-Kane","year":"2023","journal-title":"GeroScience"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjd.19677","article-title":"The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice","volume":"184","author":"Raschi","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","article-title":"Parkinson\u2019s disease","volume":"103","author":"Reich","year":"2019","journal-title":"Med. Clin. North Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.parkreldis.2019.10.002","article-title":"MRI biomarkers of motor and non-motor symptoms in Parkinson's disease","volume":"73","author":"Ryman","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/cns.14215","article-title":"Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA Adverse Event Reporting System","volume":"29","author":"Shu","year":"","journal-title":"CNS Neurosci. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-023-01334-z","article-title":"Disproportionality analysis of abemaciclib in the FDA Adverse Event Reporting System: a real-world post-marketing pharmacovigilance assessment","volume":"46","author":"Shu","year":"","journal-title":"Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11096-024-01709-x","article-title":"Unveiling the future: precision pharmacovigilance in the era of personalized medicine","volume":"46","author":"Silva","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.3390\/ijms22169015","article-title":"5-HT receptors and the development of new antidepressants","volume":"22","author":"\u015alifirski","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1529260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:47:32Z","timestamp":1735886852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1529260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":33,"alternative-id":["10.3389\/fphar.2024.1529260"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1529260","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"article-number":"1529260"}}